Comorbidities in Anti-Cyclic Citrullinated Peptide Positive At-Risk Individuals Do Not Differ from Those Patients with Early Inflammatory Arthritis

Twigg, S, Nikiphorou, E, Nam, JL et al. (6 more authors) (2018) Comorbidities in Anti-Cyclic Citrullinated Peptide Positive At-Risk Individuals Do Not Differ from Those Patients with Early Inflammatory Arthritis. Frontiers in Medicine, 5. 35. ISSN 2296-858X

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2018 Twigg, Nikiphorou, Nam, Hunt, Mankia, Pentony, Freeston, Tan and Emery. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Keywords: comorbidities; inflammatory arthritis; rheumatoid arthritis; cyclic citrullinated peptide antibodies; at-risk of arthritis; depression and anxiety disorders
Dates:
  • Accepted: 30 January 2018
  • Published: 19 February 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds)
Funding Information:
FunderGrant number
Arthritis Research UK18475
Depositing User: Symplectic Publications
Date Deposited: 02 Feb 2018 12:43
Last Modified: 16 Mar 2018 11:46
Status: Published
Publisher: Frontiers Media
Identification Number: https://doi.org/10.3389/fmed.2018.00035

Download

Share / Export

Statistics